<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Vaccination against arboviruses has been an effective strategy in limiting outbreaks. Currently a JEV and YFV vaccine is available in monovalent form
 <sup>
  <xref ref-type="bibr" rid="CR29">29</xref>
 </sup>. Similarly a tetravalent vaccine for DENV (DENV1-4) has recently been approved for use in individuals previously exposed to Dengue
 <sup>
  <xref ref-type="bibr" rid="CR30">30</xref>
 </sup>. All of these vaccines include a form of live attenuated virus (LAV) that makes the production and use of these vaccines on a large scale challenging. For example, in the case of JEV, the vaccination programs are geared towards specific regions where the diseases are endemic or in the case of an outbreak
 <sup>
  <xref ref-type="bibr" rid="CR10">10</xref>
 </sup>. Furthermore, the safety issue of live viruses precludes vaccination of certain group of people including immunocompromised individuals and pregnant women. This is especially relevant in the case of ZIKV vaccination where the target population is largely going to be pregnant women.
</p>
